PKR-Associated Compounds Targeting Lysosomal Function in Resistant Cancers

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing treatments for PKR-associated diseases, such as cancer and neurodegenerative diseases, are inadequate due to the unclear role of PKR in misfolded protein expression and lysosomal function, leading to resistance to radiation and chemotherapy.

Innovation Solution

Development of PKR-associated compounds, such as Pac 1 and Pac 2, which modulate PKR expression and lysosomal function to selectively target and inhibit cancer cells, enhance brain cell excitability, and reduce inflammation, by binding to PI4K2A and disrupting the PKR/PI4K2A network.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional chemotherapy and radiation therapy are used to treat PKR-associated diseases, then some cancer cells can be killed, but PKR-positive cancer cells develop resistance to these therapies

Engineering Contradiction:

Improvetreatment efficacyVSAvoidresistance to therapy

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent extracts and targets the specific PKR pathway in cancer cells by administering PKR inhibitors to selectively interfere with the survival mechanism of PKR-positive cancer cells, thereby overcoming the resistance developed against conventional therapies that do not target this specific pathway

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent changes the therapeutic parameter from general cytotoxicity (conventional chemotherapy) to specific pathway inhibition (PKR inhibition), thereby treating PKR-positive cancer cells that have become resistant to traditional approaches while sparing PKR-negative cells

Inventive Principle:

Principle #35Parameter changes

2Productivity

If PKR expression is high in cancer cells to promote survival, then cancer cell growth is enhanced, but this same PKR expression makes cells vulnerable to PKR inhibitor treatment

Engineering Contradiction:

Improvecancer cell growthVSAvoidsusceptibility to treatment

Core Design Contradiction:

ProductivityVSReliability

Solution Approach 1:

The patent converts the harmful overexpression of PKR in cancer cells (which promotes their survival and resistance) into a therapeutic vulnerability by administering PKR inhibitors that specifically target and inhibit this overexpressed pathway, thereby turning the cancer cells' own survival mechanism against them

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

3Reliability

If lysosomal function is enhanced to clear misfolded proteins in cancer cells, then cell survival is improved, but this same function can be disrupted by PKR inhibition to induce cell death

Engineering Contradiction:

Improvecell survivalVSAvoidlysosomal dysfunction

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent uses PKR inhibitors as intermediaries to disrupt the connection between PKR expression and lysosomal function in cancer cells, thereby inducing lysosomal dysfunction and cell death in PKR-positive cells while leaving normal cellular functions relatively intact

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentUS12465610B2Compounds and methods for the treatment of PKR-associated diseases

Publication Date: 2025.11.11 BOARD OF RGT THE UNIV OF TEXAS SYST

AI summary

Provided herein are RNA-dependent protein kinase (PKR)-associated compounds for the treatment of PKR-associated disorders including cancer, neurodegenerative diseases, and inflammatory conditions.